Science1207d left
Will the FDA approve VERVE-102?
Make a prediction1 vote
Resolution
Criteria
If the FDA approves VERVE-102 for marketing before Jan 1, 2030, then the market resolves to Yes.
Source
Kalshi (kalshi.com)
Context
VERVE-102 is a novel therapy developed for treating certain medical conditions, currently under review by the FDA for potential marketing approval. The FDA's decision will significantly impact the drug's availability and the company's future. Researchers and investors are eagerly awaiting the outcome.
Recent News
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia - PR Newswire
PR Newswire
- Lilly buys three vaccine makers; PCSK9 base editor shows promise - BioWorld News
BioWorld News
- FDA Grants Fast Track Designation to VERVE-102 Gene Therapy - HCPLive
HCPLive
Closes 1207d left
Resolves Jan 1, 2035, 3:00 PM UTC
Discussion
Sign in to join the discussion.